Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Iptacopan
Iptacopan is a substance that blocks part of the immune complement system to prevent red blood cell destruction in certain rare blood disorders.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Robert Debre University Hospital
#3500:Service Hématologie-Immunologie
Le Pré-Saint-Gervais, France
Charite Universitaetsmedizin Berlin KöR
3603: Klinik für Pädiatrie mit Schwerpunkt Hämatologie/ Onkologie
Berlin, Germany
Medical Center - University Of Freiburg
3602: Kinder- und Jugendklinik
Freiburg, Germany

Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.